Furthermore, we demonstrated that the anti-tumor efficacy was markedly enhanced by co-administration of DSP-0509 with either an IDO1 inhibitor or an AXL inhibitor, although involvement of diverse immune cell except for Tregs and macrophages needs to be examined in the future study. The gene discussed is IDO1; the disease is neoplasm.